Free Newsletter
Chavez: Drugs shouldn't get patented
Venezeula may join the ranks of patent-bucking countries. President Hugo Chavez says he's set on shaking up intellectual property rules because patents "have become a barrier to production, and we cannot allow them to be barriers to medicine," Reuters reports. Scientific discoveries and inventions should be "knowledge for the world," he maintains.
The socialist leader has nationalized some Venezuelan industries, and recently threatened to take over a Pfizer plant in the country. By abolishing patents, Chavez would clear the way for domestic drugmakers to manufacture versions of branded meds. Commerce Minister Eduardo Saman, who's one of Chavez's close cronies, characterized the patent changes as an act of defiance against global Big Pharma. "We cannot allow transnational medicine companies to impose their rights on the Venezuelan people," he said on state television.
The drugs industry in Venezuela is up in arms, of course. Edgar Salas, who runs the pharma chamber of commerce, warned that invalidating patents could scare drugmakers away from the Venezuelan market completely. Venezuela could face drug shortages and lose foreign investment, Salas said.
- read the story from PharmacyEurope
- see the Reuters news
Related Articles:
Brazil mulls patent-busting on Tenofovir
India lets pharma fight compulsory licenses
Courts more open to patent-busting
Comments
By Communism Stinks | Posted 5:48pm | June 23, 2009
Communism/Socialism/Liberalism has this kind of mentality but what happens when you actually start to enforce it?
If drug companies cannot make profits from new drugs, why would they make them in the first place? Out of the kindness of their hearts? Who is going to pay their employees? Who is going to pay the cost of R&D?
Once the incentive to create new drugs to help people is gone, there is no reason to create the drug at all...meaning, the people will ultimately suffer for it.
Of course, in this instance it will be the U.S. consumer that gets bent over as usual.
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: